

Socioeconomic Impact of Novel Therapeutics on CVD Incidence and Outcomes

Todd Anderson

There is a growing interest in bending the cost curve with respect to health care expenditures. The current growth in cost is not sustainable. The threat is not only being able to provide basic health care needs, but creates difficulty in implementation on innovative therapies that are common in CV medicine. The total health care expenditure in Canada is about \$240B last year which represents a 4% growth. This is now more than 11% of the GDP and more than \$6600 for every Canadian. Cardiovascular disease makes up about \$25B including indirect costs. The focus moving forward is applying implementation strategies for appropriateness of existing tests. We will review efforts underway to attenuate low value testing in the Canadian environment. This will create some space for the use of innovative and novel technologies or pharmaceuticals. What is the cost effectiveness of monoclonal AB for lipid disorders or inflammation? What data exists with respect to value of TAVR, mitral clip, pulmonary artery pressure monitoring devices? A brief overview will provide information on our current understanding and where research has to go in the future to best inform this rapidly evolving field.